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AGGRESSIVE AND VIOLENT BEHAVIOR – THE RESULT OF 
MALFUNCTION IN THE NEURAL CIRCUIT REGULATING EMOTION 
 
NINA RIZK 
 
ABSTRACT 
 Mental illness is currently diagnosed using subjective observational criteria as 
outlined in the 5th Edition of the Diagnostic and Statistical Manual (DSM-V), yet many 
have argued for the medicalization of the diagnosis of mental illness by incorporating 
biomedical and neuroanatomical criteria. The following literature review explores the 
neural circuit responsible for regulating emotion, as well as the structural and chemical 
alterations to this circuit that have been shown to correlate with aggressive and/or violent 
behaviors characteristic of certain types of mental illness. The neural circuit regulating 
emotion is comprised of the prefrontal cortex, the subcortical limbic system, the 
dopaminergic pathway, the serotonergic pathway, catecholaminergic neurons, and 
GABAergic neurons. Alterations to these structures or chemicals have been associated 
with major depressive disorder, suicidal ideations, substance use disorders, 
schizophrenia, and personality disorders. Medicalization of mental illness has the 
potential to serve two purposes – first, to standardize diagnosis and treatment of mental 
illness, and second, to decrease the stigma often associated with mental illness – and to 
improve outcomes for those patients living with mental illness.  
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INTRODUCTION 
 
According to the National Alliance on Mental Illness (NAMI), approximately 1 in 
5 adults in the United States experiences mental illness in a given year, and furthermore, 
approximately 1 in 25 adults in the United States experiences a serious mental illness in a 
given year that substantially interferes with major life activities. Of those experiencing 
mental illness, a disproportionately high number are members of either the state or local 
prison system, and taken together with those not imprisoned, have cost the United States 
an estimated 190 billion dollars in lost earnings per year. Individuals with mental illness 
face a growing number of challenges. In addition to the physical and mental symptoms 
associated with their diagnosis, those living with mental illness are regularly faced with 
the detrimental consequences of discrimination and stigma (Corrigan & Watson, 2004). 
Only a small proportion of individuals with mental illness are known to actually 
exhibit aggressive and/or violent behavior, which is often inaccurately deemed by society 
as a result of ‘poor character’ and ‘lack self-control’ (Corrigan & Watson, 2004). This 
behavior tends to be unjustifiably generalized to all of those living with mental illness, 
contributing to the negative judgment cast on this vulnerable population. Unbeknownst to 
most, those with mental illness who do demonstrate this behavior likely do so not by 
choice, but as a result of underlying biological mechanisms resulting from alterations in 
brain structure and function that are typically uncontrollable and unpredictable.  
Taken together, these realities have led a rising number lawmakers and health 
care professionals to call for a transformation in the diagnosis of mental illnesses in order 
 2 
to increase understanding and compassion among the general public. It has been 
proposed that modern aspects of clinical medicine be incorporated with traditional 
behavioral observation when diagnosing mental illnesses, particularly those associated 
with aggressive and/or violent activities (Hyman, 2007; Insel et al., 2010; Cuthbert & 
Insel, 2013).  
Suggestions from Corrigan and Watson (2004) highlight two possible and 
accurate alternatives for educating the public about mental illness. The first is to describe 
mental illness as a disease of the brain, and therefore a disease with neurobiological and 
physiological roots that may be addressed in the course of individual treatment. The 
second is to describe mental illness as a result of environmental stressors, and 
subsequently a disease with social and psychological causes that may be alleviated by 
minimizing traumatic triggers that exist in the individual’s environment. Either way, 
incorporating these descriptions into diagnosis and reducing the stigma and 
discrimination associated with aggressive and/or violent symptoms associated with 
mental illness is an imperative issue of public health concern which demands attention 
and which will inevitably require a vocal and multidimensional approach to resolution. 
Current Method of Diagnosing Mental Illness  
The current method of clinically diagnosing mental illness is by using either the 
5th Edition of the Diagnostic or Statistical Manual of Mental Disorders (DSM-5) created 
by the America Psychological Association or the 10th Edition of the International 
Classification of Diseases (ICD-10) created by the World Health Organization, which are 
comprehensive and descriptive catalogues of identified mental illnesses and their 
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associated symptoms. These catalogues are constantly undergoing revision, because our 
knowledge of the field is constantly developing to fill in gaps where information was 
previously nonexistent. Historically and currently, the diagnosis of mental illness relies 
exclusively on subjective characteristics (Hyman, 2007; Insel et al., 2010; Cuthbert & 
Insel, 2013). In fact, the diagnosis of mental illness depends solely on clinical 
observations of the timing, clustering, and resolution of symptoms and has generally 
ignored the exploration of the pathophysiology accompanying mental illness (Hyman, 
2007).  
Unfortunately, it has been found that the diagnostic categories outlined in existing 
literature fail to align with recent scientific and genetic findings, and fail to clarify the 
underlying pathological mechanisms that are associated with symptomatic behaviors 
(Corrigan & Watson, 2004). This discrepancy has motivated a reform in the process of 
diagnosing mental illness, although there is no consensus about the best way to achieve 
this goal (Hyman, 2007; Insel et al., 2010; Cuthbert & Insel, 2013). Higher brain function 
is extremely complex and often misunderstood, which is why the field is continually 
evolving with new imaging techniques and data collection methods. It is believed that the 
most comprehensive diagnosis of a mental disorder will only come with the consideration 
of a combination of clinical observations, neurobiological information, and family and 
genetic studies (Hyman, 2007).  
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Proposed Method of Diagnosing Mental Illness  
The National Institute of Mental Health (NIMH) launched the Research Doman 
Criteria (RDoC) project in 2009 with the goal of creating a framework for research on 
neurobiological pathology that will later influence diagnostic classifications of mental 
illness (Insel et al., 2010). The primary focus of the RDoC project is neural circuity – the 
idea that neurons, the working unit of the brain and nervous system, are connected in 
intertwining networks responsible for various response and regulation activities 
(Davidson, Putnam & Larson, 2000; Insel et al., 2010; Cuthbert & Insel, 2013). These 
neural circuits control specific and distinct functions by coordinating with one another to 
form specialized brain systems. When these systems are working as intended, human 
beings are capable of living in the world by appropriately and effectively interacting with 
their environments. According to the NIMH, when these systems malfunction, human 
beings exhibit altered behavior that is considered to be abnormal and atypical of the 
society in which they live.  
The initiation of the RDoC project rests on three key assumptions: (1) mental 
illnesses are brain circuit disorders, (2) tools of neuroscience are able to detect 
dysfunctions in brain circuits, and (3) data collected in neuroscience will produce unique 
results that supplement clinical observation (Insel et al., 2010; Cuthbert & Insel, 2013). 
The hope for the short term is that the project will allow for brain-behavior relationship 
mapping, but long term, the hope is that RDoC will provide an additional dimension to 
psychopathology. The NIMH plans to collaborate with both the American Psychological 
Association (APA) and the World Health Organization (WHO) in using the research 
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garnered from the RDoC project to add molecular and neurobiological parameters to 
future diagnostic systems and to implement neuroscience-based psychiatric 
classifications into the field of mental illness (Davidson et al., 2000; Insel et al., 2010; 
Cuthbert & Insel, 2013).  
The Neural Circuit of Emotion-Regulation 
Mental illnesses are considered “brain disorders that primarily affect emotion, 
higher cognition and executive function” (Hyman, 2007, p. 725), indicating that 
understanding the connectivity of the neural circuits of the brain is essential in 
understanding mental illness. The neural circuit of primary interest is that which regulates 
human emotion. If this circuit is interrupted, it is inevitable that there will be neurological 
and/or behavioral consequences. In fact, multiple studies have demonstrated that any 
abnormalities affecting the structure or functionality of this neural circuit will result in an 
increase in the susceptibility of an individual to aggression and violence that is often 
manifested in very particular mental illnesses (Davidson et al., 2000; Nelson & 
Chiavegatto, 2001; Nelson & Trainor, 2007; Siever, 2008).  
The neural circuit responsible for influencing emotional regulation and social 
behaviors is proposed to include a combination of the prefrontal cortex (PFC), the 
subcortical limbic system, the dopaminergic pathway, the serotonergic pathway, the 
catecholaminergic neurons, and the GABAergic neurons. A malfunction in this circuit 
has been shown to result in abnormally high levels of aggression and violence, 
particularly in individuals who have certain mental illnesses (Davidson et al., 2000; 
Nelson & Chiavegatto, 2001; Nelson & Trainor, 2007; Siever, 2008).  
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Components of the Neural Circuit of Emotion-Regulation 
In order to understand how neural circuit dysfunction might affect behavior, it is 
first necessary to understand the functions of the various structures included in the 
system. The main function of the PFC is to serve as a control center by coordinating 
thoughts and actions in accordance with internal goals, so its critical role means that it is 
densely connected with many other regions of the brain. The PFC receives and processes 
information regarding emotion and reward, and is involved in the initiation of executive 
cognitive functions and response inhibition (Nelson & Trainor, 2007, Seiver, 2008). The 
PFC has been shown to inhibit certain inputs to the structures of the limbic system that 
are known to promote aggressive behavior, and reduced activation of the PFC has been 
associated with increased impulsive aggression. Deficits in this area are expected to result 
in poor planning and organization, difficulty with inhibitory control and reward 
punishment processing, and altered ethical reasoning (Yang, Glenn, & Raine, 2008).  
The subcortical limbic system includes the anterior cingulate cortex (ACC), 
amygdala, and hippocampus, as well as several other brain regions. The ACC is an 
integral part of the limbic system, and processes emotion information separately from 
cognitive information (Bush, Luu & Posner, 2000). The rostral section of the ACC, 
functions as an emotion-processor, is primarily concerned with instinct and mood and 
specializes in the regulation of emotional responses (Davidson et al., 2000). The caudal 
section of the ACC, functions as a cognitive-processor, alternatively specializes in the 
detection of conflicts and monitoring of errors. Deficits in the ACC are expected to result 
in lack of empathy, poor problem solving, and decreased emotional regulation (Yang et 
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al., 2008). In fact, lesions of the ACC are correlated with apathy and emotional instability 
(Bush et al., 2000). 
The amygdala and the hippocampus work in tandem to form the amygdala-
hippocampal complex. The main function of the amygdala is to process stimuli with 
emotional and social significance, specifically facial expressions of emotion as well as 
stimuli related to fear and visible threats that induce fearful responses (Morgane, Galler 
& Mokler, 2005; Adolphs, Baron-Cohen, & Tranel, 2002). The main function of the 
hippocampus is to monitor emotional memory by remembering contextual information 
concerning negative stimuli. Deficits in the interaction of these areas are expected to 
result in problems with fear perception and regulation of emotion (Yang et al., 2008). 
This may lead to alterations and deficits in social behavior by way of impaired judgment 
and relationships (Blair & Fine, 2000). 
 
 
 
 
 
 
Figure 1: Brain Structures Involved in the Neural Circuit of Emotion 
Taken From http://www.nimh.nih.gov/health/educational-resources/brain-basics/brain-
basics.shtml 
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The combination of the PFC and the amygdala are of particular interest to 
investigators of mental illness, and is implicated in psychopathy in the form of a variety 
of aggressive and/or violent behaviors associated with certain mental illnesses (Blair, 
2007). Psychopathy is defined as emotional dysfunction that is demonstrated by 
impulsivity, poor behavioral control, and reduced empathy, and is incorporated into the 
DSM-5 as a descriptive symptom rather than a direct diagnosis (Blair, 2007; de Oliveira-
Souza, 2008). Individuals with psychopathy are at risk for heightened aggressive and/or 
violent behavior and reduced moral-conventional distinction, both attributes that are often 
associated with individuals diagnosed with certain mental illnesses. 
The dopaminergic pathway consists of the structural ventral tegmental area 
(VTA) and nucleus accumbens (NAc), as well as the chemical neurotransmitter 
dopamine. Dopamine is related to reward and motivations, and levels of dopamine are 
indicative of the motivational aspects of aggression (Miczek, Fish, De Bold, & De 
Almeida, 2002). This reward system is activated by an aggressive encounter, and leads to 
aggressive behavior in the absence of sufficient inhibition and control by the PFC. As a 
result, increases in extracellular dopamine levels have been associated with the 
anticipation of and response to aggressive encounters, and anti-psychotic medications 
may act as either antagonists to dopamine (D2) receptors to minimize the display of 
aggressive behaviors (Miczek et al., 2002). 
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Figure 2: The Dopaminergic Pathway in the Brain 
Taken From 
https://www.ncbi.nlm.nih.gov/books/NBK11035/figure/A412/?report=objectonly 
 
The serotonergic pathway consists of the structural substantia nigra and raphe 
nuclei, as well as the chemical neurotransmitter serotonin (Fibliger & Miller, 1977), 
which has a reciprocal association with aggressive and/or violent behaviors (Miczek et 
al., 2002). Serotonin is related to the suppression of aggressive behaviors, and levels of 
serotonin are indicative of the inhibition of aggression (Siever, 2002). As a result, 
decreases in extracellular serotonin levels have been associated with similar behaviors. 
Consequently, anti-psychotic medications may act as agonists and reuptake inhibitors to 
serotonin (5-HT) receptors to minimize the display of aggressive behaviors (Miczek et 
al., 2002). 
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Figure 3: The Serotonergic Pathway in the Brain 
Taken From 
https://www.ncbi.nlm.nih.gov/books/NBK11035/figure/A412/?report=objectonly 
 
The catecholaminergic neurons of the brain lower the threshold for an aggressive 
response to environmental stimuli and serve a modulating function through the 
production of the norepinephrine neurotransmitter (Volavka, Bilder, & Nolan, 2004; de 
Almeida, Ferrari, Parmigiani, & Miczek, 2005). High plasma levels of norepinephrine – 
either from increased production of decreased reuptake – have been correlated in animal 
studies with elevated aggressive and/or violent behaviors, indicating a positively 
correlated relationship similar to that of dopamine. The activity of catecholaminergic 
neurons is directly influenced by the catabolic enzymes catechol-O-methyltransferase 
(COMT) and monoamine oxidase A (MAOA), which are regulated by the transcriptional 
activity of associated genes.  
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Figure 4: The Catecholaminergic Pathway in the Brain 
Taken From 
https://www.ncbi.nlm.nih.gov/books/NBK11035/figure/A412/?report=objectonly 
 
The GABAergic neurons of the brain interact with both dopaminergic and 
serotonergic neurons and serve a modulating function through the production of the 
gamma-amino butyric acid (GABA) neurotransmitter (Miczek et al., 2002). High plasma 
levels of GABA – either from increased production or decreased reuptake – have been 
correlated in animal studies with suppressed aggressive and/or violent behaviors, 
indicating a negatively correlated relationship similar to that of serotonin. 
Benzodiazepines act as indirect positive allosteric modulators of GABA receptors in the 
brain, and have been clinically shown to reduce aggressive and/or violent behavior via 
tranquilizing, anti-anxiety, sedative, and muscle-relaxing effects (Miczek et al., 2002; de 
Almeida, Ferrari, Parmigiani, & Miczek, 2005).  
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Figure 5: Major Elements of the GABAergic Synapse 
Taken From 
https://openi.nlm.nih.gov/detailedresult.php?img=PMC3181687_DialoguesClinNeurosci-
4-261-g003&req=4 
 
Dysfunction in the Neural Circuit of Emotion-Regulation 
Aggression is defined as “hostile, injurious, or destructive behavior” (Siever, 
2008, p. 429) and is a symptom of a small number of mental illnesses, including major 
depressive disorder (MDD) accompanied by suicidal ideations, substance-use disorders 
(SUDs), schizophrenia, antisocial personality disorder (APD), and borderline personality 
disorder (BPD), to name a few. Aggression is a complex social behavior with multiple 
causes, originating with the organism’s needs to compete for mates and resources, and 
stemming from corresponding changes in neural activity (Blair, 2001; Nelson & 
Chiavegatto, 2001).  
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Controlled-instrumental aggression is characterized as more purposeful and goal-
oriented (e.g. fighting someone who poses a threat), and is a ‘top-down’ process that is 
initiated in the PFC in a proactive and premeditated fashion (Blair, 2001; Nelson & 
Chiavegatto, 2001; Nelson & Trainor, 2007; Seiver, 2008). On the other hand, reactive-
impulsive aggression can result in heightened, enduring, or inappropriate aggressive 
responses (e.g. mass killings or assassinations), and is a ‘bottom-up’ process that is 
initiated in the limbic system in response to an immediate threat and emotions such as 
anger or fear. Generally, it is the reactive-impulsive type of aggression that is considered 
to result from abnormalities in either the structures or the neurotransmitter that make up 
the circuit responsible for regulating emotional regulation and social behavior. 
Davidson, Putnam, and Larson (2000) argue that the tendency for impulsive 
aggression is associated with a failure to respond appropriately to the expected negative 
consequences of behaving aggressively and with a low threshold for activating negative 
emotion. They found that the mechanism underlying the suppression of negative emotion 
is an inhibitory pathway from the PFC to the amygdala, so when the PFC is damaged, it 
is no longer effective in inhibiting the amygdala and the brain takes much more time to 
extinguish aversive responses to negative stimuli. After examining brain images from 
various subjects by way of functional magnetic resonance imaging (fMRI), the 
researchers were able to infer that there are objectively measurable differences between 
individuals regarding their ability to regulate emotions. Further, both patterns of PFC 
activation and emotion regulation skills are able to predict whether an individual is 
vulnerable to impulsive aggression and / or violent behavior.  
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The role of serotonin was also examined (Davidson et al., 2000), as the PFC 
contains a high density of serotonin receptors. Serotonin is believed to have inhibitory 
control over impulsive aggression, so the greater the concentration of serotonin, the more 
able individuals are to prevent aggressive reactions to aversive stimuli. Normal 
individuals are therefore able to voluntarily process negative stimuli and regulate the 
resulting negative affect. The researchers also examined the role of the amygdala in 
particular, finding that too much activation of the amygdala can lead to excessive 
negative affect and too little activation of the amygdala can lead to decreased sensitivity 
to social cues.  
For further supporting research, Bufkin and Luttrell (2005) reviewed seventeen 
separate neuroimaging studies with the purpose of determining the precision and 
accuracy of different structural and functional techniques used to correlate certain aspects 
of the brain with aggressive and/or violent tendencies. Techniques such as single-photon 
emission computed tomography (SPECT), positron emission tomography (PET), 
magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI) 
allow researchers and clinicians to view the brain in ‘real time’ as it is reacting to stimuli 
and directing emotional responses.  
These studies confirmed the results mentioned above in prior studies by finding 
three consistent patterns: (1) a link between PFC pathology and aggressive or violent 
behavior, (2) a link between disproportionately low PFC activity in comparison to 
amygdala activity and aggressive and/or violent behavior, and (3) that there is indeed an 
intricate neural circuit involved in the regulation of emotion and its associated behaviors. 
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Bufkin and Luttrell (2005) go on to describe the ways in which these findings may be 
utilized by lawmakers and mental health professionals in reform efforts. Traditionally, 
there has been an aversion to considering the intersectional factors affecting aggressive 
and/or violent criminal behavior. This aversion has had dire consequences, as it avoids 
the reality that mental illnesses and criminality are often a result of a number of social, 
psychological, structural, and environmental factors. With comprehensive analysis, which 
is further explored below, criminality and mental illness may be more deeply understood, 
more effectively prevented, and more appropriately treated.  
Most of studies assessing the role of catecholinergic neurons in the brain examine 
the role of particular genes in influencing aggressive and/or violent behaviors (Volavka, 
Bilder, & Nolan, 2004; de Almeida, Ferrari, Parmigiani, & Miczek, 2005). Low 
transcription of COMT and MAOA genes leads to lowered enzymatic activity of COMT 
and MAOA, and subsequently increased levels of norepinephrine and enhanced 
aggressive and/or violent behavior. This theory has been supported by animal studies, in 
which COMT and MAOA knockout mice demonstrated elevated aggressive and/or 
violent behaviors (Volavka, Bilder, & Nolan, 2004). This relationship represents a 
significant contribution to the understanding of the gene-environment interaction related 
to aggressive and/or violent behavior, as the results of these studies suggest that 
alterations in genotype may impact an individual’s sensitivity to environmental triggers 
of aggressive and/or violent behavior.  
These relationships have also been supported by human studies, in which 
evaluations of distinct human populations in the Netherlands, Israel, Germany, and New 
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Zealand found an association between the valine (VAL) high-activity allele to methionine 
(MET) low-activity allele resulting in polymorphism and lower COMT enzymatic 
activity and the demonstration of aggression and/or violence towards self and others 
related to a diagnosis of mental illness (Volavka, Bilder, & Nolan, 2004). In addition, 
MAOA is known to be involved in the metabolism of dopamine, serotonin, and 
norepinephrine, demonstrating its intimate connection with the neurotransmitters 
involved in the neural circuit regulating emotion (Gerrra et al., 2004). Human studies 
have shown that low-activity MAOA-3 polymorphism in the promoter region of the 
structural gene for MAOA has been associated with both aggressive and/or violent 
behavior and diagnosis of psychiatric disorders. 
The majority of studies assessing the inhibitory role of GABAergic neurons in the 
brain examine the role of particular drugs in influencing aggressive and/or violent 
behaviors (Siegel, Bhatt, Bhatt, & Zalcman, 2007). One such drug, valproic acid, 
enhances GABAergic function by preventing its conversion to glutamate. In one study, 
when valproic acid was administered to patients with organic brain syndromes, the 
patients were observed to have a 50% reduction in aggressive and/or violent behavior. 
Another such drug, divalproex, is also known to actively increase GABA levels in the 
brain, although the exact mechanism is not known. In a different study, when divalproex 
was administered to patients with personality disorders, the patients were observed to 
have significant reduction in irritability and impulsive aggression/violence. A third drug, 
topiramate, enhances GABAergic activity by activating neuronal chloride channels. In a 
related study, when topiramate was administered to patients with personality disorders, 
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the patients demonstrated improved scores on various scales measuring anger. Taken 
together, these studies provide support for the thesis that GABA and those drugs that 
enhance or mimic the activity of GABA are effective in minimizing aggressive and/or 
violent behavior.  
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SPECIFIC AIMS 
Specific aims of the following thesis include: 
1. Comprehensive review of literature to characterize the structural and chemical 
features of the neural circuit regulating emotion and corresponding behavior.  
2. Investigation into the current evidence for a correlation between aggressive and/or 
violent behaviors and malfunction in the neural circuit regulating emotion.  
3. Conclusion on the validity of the potential use of brain imaging techniques to 
assist with the diagnosis of aggression- and/or violence-associated mental illness.  
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PUBLISHED STUDIES 
Major Depressive Disorder and Suicidal Ideations 
The DSM-5 defines major depressive disorder (MDD) as the presentation of five 
or more of the following symptoms for an extended time during the same two-week time 
period: 1) depressed mood, 2) markedly diminished interest in activity, 3) significant 
unexplained weight loss, 4) insomnia or hypersomnia, 5) psychomotor agitation, 6) 
fatigue or loss of energy, 7) feelings of worthlessness, 8) diminished ability to 
concentrate, and 9) recurrent suicidal ideations. The following studies review the possible 
relationship between MDD and alternations in brain structure and function.    
Wagner et al., (2011) explored the prevalence and detrimental effects of MDD in 
the context of alterations in brain structure, finding that reduced density in the gray 
matter (GM) of particular areas of the brain was associated with suicidal ideations among 
some of those with MDD. Although MDD is one of the top five leading causes of 
morbidity and mortality and the risk of suicide has been found to be as much as 17 times 
higher in people with mood disorders compared to the general population, most people 
with mood disorders do not actually attempt suicide. Because not all individuals with 
mood disorders express suicidal ideations and engage in suicidal behaviors, investigators 
hypothesize that there may be an underlying biological predisposition for this 
demonstration of aggressive and/or violent behavior in certain – but not all – individuals 
who are diagnosed with mood disorders.  
 Wagner et al. (2011) first compared 30 healthy control subjects to 30 patients with 
MDD, finding that those with MDD showed significantly decreased GM in the PFC and 
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the amygdala-hippocampal complex. The researchers then separated the 30 patients with 
MDD into two distinct groups – a high-risk group was comprised of individuals who 
either had attempted suicide in the past or who identified a first-degree relative who had 
attempted suicide in the past, and a low-risk group was comprised of individuals who did 
not meet the high-risk criterion. Compared to the 15 healthy control subjects, the 15 high-
risk MDD patients demonstrated significantly deceased GM in the PFC, the amygdala-
hippocampal complex, and the ACC. These significant differences were not found in the 
comparison between healthy control subjects and low-risk MDD patients. Wagner et al. 
(2011) then compared both groups of MDD patients, discovering significantly deceased 
GM in the ACC of high-risk MDD patients compared to low-risk MDD patients.  
 This study importantly points out that brain alterations in the neural circuit 
regulating emotion are not only associated with MDD, but are additionally associated 
with the aggressive and/or violent thoughts against oneself that accompany suicidal 
ideations. These volumetric reductions in fronto-limbic GM support the idea that the PFC 
and components of the limbic system are involved in reduced emotional and behavioral 
control, correlated with aggressive and/or violent behavior. The investigators further posit 
that the findings provide evidence that this predisposition to suicidal ideations is 
independent of the diagnosis of MDD (Wagner et al., 2011). 
Arrango, Underwood, Gubbi, and Mann (1995) utilized a different approach by 
focusing on alterations in two distinct serotonin binding sites in the brain – pre-synaptic 
serotonin transporters and post-synaptic serotonin 5-HT receptors – in the PFC of 
individuals who had committed suicide. The researchers hypothesized that reduced levels 
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of serotonergic activity in the brain and cerebrospinal fluid (CSF) would be associated 
with an increased risk of suicide, pointing out that reduced serotonin has been previously 
identified in suicidal patients diagnosed with MDD, schizophrenia, and a variety of 
personality disorders associated with a vast majority of suicides. Selective ligands were 
used to locate and map both pre-synaptic and post-synaptic serotonin binding sites post-
mortem in the brains of both healthy control subjects and individuals who had committed 
suicide. 
The results of this study are fascinating, showing a decrease in the binding of 
serotonin to the pre-synaptic transporter and an increase in the binding of serotonin to the 
post-synaptic receptor in the PFC of patients who had committed suicide when compared 
to patients who had not committed suicide (Arrango et al., 1995). Additionally, it was 
found that actual levels of serotonin and its primary metabolite were lower in the CSF of 
patients who had committed suicide when compared to patients who had not committed 
suicide. As a result, the investigators predicted that their observations reflected natural 
coping mechanisms employed by the body in response to low levels of serotonin – a 
downregulation of the pre-synaptic transporter and an upregulation of the post-synaptic – 
with the goal of increasing serotonin levels in the CSF of individuals who ended up 
committing suicide.  
Ryding, Lindström, and Träskman-Bendz (2008) examined the role of dopamine 
in suicidal behavior, in addition to supporting the findings mentioned that low serotonin 
levels and suicidal behavior are linked. In addition MDD, schizophrenia, and a variety of 
personality disorders, they claim that suicidal ideations are also associated with SUDs 
 22 
and anxiety, not to mention circumstances of childhood abuse, poor living conditions, 
and even serious physical diseases such as epilepsy or cancer. The investigators reviewed 
a number of both human and animal studies to conclude that serotonin decreases 
aggression by stimulating the PFC and inhibiting the NAc, whereas dopamine directly 
increases aggression by stimulating the NAc. These findings were consistent with the 
discovery that individuals with suicidal ideations had lower levels of serotonin and higher 
levels of dopamine, both of which contribute to the portrayal of aggressive and/or violent 
behavior. On a related note, Ryding et al. (2008) noted that consumption of alcohol and 
certain classifications of drugs resulted in an increase in brain dopamine concentrations, 
further exacerbating the risk of suicide.  
Dannlowski et al. (2009) studied an additional aspect of the relationship between 
the amygdala and both the PFC and the ACC contributing to MDD, one involving the 
MAOA gene in particular. The investigators recruited 34 individuals diagnosed with 
MDD and 31 healthy control subjects, interested in further researching the 
pharmacological mechanisms in which MAOA inhibitors serve as effective drugs for the 
treatment of MDD. The investigators employed PCR and electrophoresis to determine 
genotype as either MAOA-3 (high-risk) or MAOA-4 (low-risk) based on the length of a 
particular region of the gene. The investigators employed fMRI techniques to measure 
activity in the amygdala, PFC, and ACC regions of the brain. Dannlowski et al. (2009) 
found that the connectivity between the amygdala and both the PFC and the ACC is 
significantly reduced in individuals diagnosed with MDD, a connectivity that is 
modulated by the MAOA gene, which considerably predicts the severity of illness. Of 
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note, those individuals with the MAOA-3 were found to have the most reduction in PFC-
amygdala and in ACC-amygdala connectivity and the strongest association with 
emotional disorders.  
Sequeira et al. (2009) studied the association between the GABAergic system and 
the act of suicide. The investigators examined 663 samples from 39 brains from the 
Quebec Suicide Brain Bank. The samples were taken from male subjects of French-
Canadian origin and were divided into three distinct groups for examination. 16 of the 
brains examined belonged to individuals who committed suicide and who had a history of 
MDD, 10 of the brains examined belonged to individuals who committed suicide but who 
had no history of MDD, and 13 of the brains examined belonged to healthy control 
subjects who died suddenly from causes other than suicide and who had no history of 
MDD. The investigators used genome-wide microarrays to assess gene expression in the 
brain areas believed to be involved in the neurobiology of suicide and MDD. Sequeira et 
al. (2009) identified a clear pattern of GABAergic gene dysregulation among the brain 
samples belonging to individuals who committed suicide and who had a history of MDD, 
primarily in the PFC and hippocampal regions of the brain.  
Croarkin, Levinson, and Daskalakis (2011) discovered similar findings regarding 
the association between the GABAergic system and MDD, operationally describing 
GABA as a neurotransmitter responsible for regulating neuronal excitability through 
inhibitory feedback loops in the central nervous system. The investigators concurred that 
the PFC, amygdala, and hippocampus of the brain are all rich in GABAergic neuronal 
projections, which selectively attenuate the firing of other neurons through cortical 
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inhibition. There is evidence that dysfunctional cortical inhibition may contribute to the 
onset of MDD as it plays a role in the regulation of mood and cognition in affective 
disorders. The authors discussed a number of studies providing further evidence of this 
connection. For example, one study showed that individuals with MDD had significantly 
decreased size and density of GABAergic neurons in the PFC, indicative of significantly 
impaired cortical inhibition. Another study found that individuals with MDD tended to 
have decreased levels of GABA in the cerebrospinal fluid (CSF). Yet another study 
reported that the PFC of victims of suicide exhibited reduced mRNA expression of a 
number of GABA receptor subunits when compared to healthy control subjects. All of 
these findings imply that GABA plays an essential role in the pathophysiology of MDD. 
 Luscher, Shen, and Sahir (2011) also conducted studies to quantify the connection 
between the GABAergic system and MDD, focusing on the role of early- and late-onset 
stress in the development of MDD. The investigators found that this stress directly 
affected the concentration of GABA in the CSF and the alteration of the subunits of 
GABA receptors in the brain. A large body of epidemiological evidence has shown that 
stress is a major vulnerability factor for mood disorders, including MDD. The 
investigators found that stress during childhood causes a reduction in the expression of 
GABA receptors in the child brain. Similarly, the investigators found that chronic stress 
during adulthood causes changes in the expression and function of GABA receptors as 
well as reductions in GABAergic synaptic transmissions in the adult brain.  
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Substance Use Disorders 
 The DSM-5 defines substance-use disorders (SUD) on a continuum scale in 
which an individual with a mild SUD displays fewer symptoms than an individual with 
either a moderate or severe SUD. The criteria for diagnosis include a number of 
indicators, such as spending significant time to obtain the substance, consuming the 
substance in large amounts over long periods of time, being unable to stop use of the 
substance despite the desire to quit, impaired control and craving of the substance, 
difficulty conducting major life activities, continuing substance use despite strained 
social interactions, risky use of the substance in hazardous situations, and the 
manifestation of pharmacological indicators such as physiological tolerance and 
withdrawal symptoms.  
Oscar-Berman and Marinković (2007) studied the neurobiological relationship 
between alcohol – a commonly misused substance – and aggressive and/or violent 
behavior. Although there are quite a few contributing factors to the development and 
maintenance of alcoholism – namely age, gender, health, and family history – certain 
structural and functional neural changes have been observed across the board. It is a 
common belief that alcohol abuse and dependence lead to aggression and reduced 
impulse control, and there is a high correlation between alcohol consumption and violent 
crime, with intoxication commonly leading to an increased likelihood of aggressive 
behavior. This aggressive behavior is exhibited by way of impulsivity, disinhibition, 
social or sexual inappropriateness, and executive function impairment. Certain brain 
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structures in particular are vulnerable to the effects of alcoholism, including the PFC and 
the amygdala-hippocampal complex.  
Studies have shown a decreased neuron density and a decreased level of regional 
blood flow in the PFC of alcoholics, causing a reduction in overall volume (Oscar-
Berman & Marinković, 2007). It is speculated that this leads to a series of negative 
consequences, such as impaired attention and perception, disrupted self-awareness, and 
diminished ability to recognize facial expression of emotion. All of these consequences 
lead to aggression and a lack of concern for the consequences of one’s own behavior. 
Alcohol has further effects on the limbic system, as its consumption is correlated with 
hypo-responsiveness of the amygdala-hippocampal complex. The amygdala serves to 
process the significance of major emotions such as love, fear, rage, and anxiety, so it is 
important in identifying danger. The hippocampus is also part of the brain system 
associated with fear and anxiety. Alcohol has been shown to negatively impact 
neurogenesis in both regions by hindering cell proliferation and cell survival, resulting in 
decreased overall volume.  
Chen et al. (2007) report similar findings in their study of the impulsivity and 
disinhibition that often accompanies SUDs by using electroencephalograms (EEGs) and 
event-related potentials (ERPs) to assess dynamic brain structures and processes. Both 
healthy control subjects and individuals diagnosed with alcohol-use disorders were 
evaluated for impulsivity by self-report questionnaires and then underwent various EEG 
and ERP testing in response to stimuli. Those individuals diagnosed with an alcohol-use 
disorder were found to have both reduced amplitude activity in the PFC and elevated 
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scores in non-planning, motor impulsivity, and cognitive impulsivity. Even further, an 
examination of offspring showed that the children of healthy control subjects tended to 
have more PFC activity and less impulsive behavior than the children of individuals 
diagnosed with alcohol-use disorders, independent of the disorder-status of the offspring. 
This supports the presence of an additional genetic component to alterations in brain 
structure and function.  
 Another study conducted by Schiffer et al. (2011) explored a slightly different 
angle, arguing that individuals demonstrating the aggressive and/or violent behaviors 
typically associated with psychopathy are actually the result of extensive and long-term 
substance-use. Therefore, this study was an attempt to re-allocate the diagnoses of 
offenders with aggressive and/or violent behaviors from psychopathy to SUDs to provide 
more targeted therapeutic treatment. The investigators recruited four distinct groups of 
study subjects – 12 men with SUDs and 12 men without SUDs who behaved violently 
(offenders), as well as 13 men with SUDs and 14 men without SUDs who did not 
behaved violently (non-offenders). MRIs were conducted for all study participants with 
the purpose of measuring brain GM. 
 Results showed that total brain volume did not significantly vary between the four 
study groups, however, there was a significant difference in brain GM based on the 
interaction between violent behavior and SUD (Schiffer et al., 2011). In the comparison 
of behavior-status, offenders both with and without SUDs were classified with higher 
GM volume of the amygdala and NAc when compared to non-offenders both with and 
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without SUDs, signifying the relationship between violent behavior – as well as measures 
of aggression and psychopathy – and structural alteration of the limbic system.  
This indicated that the relationship between reduced GM volume and elevated 
aggressive and/or violent behavior was independent of SUD-status. In the comparison of 
SUD-status, those offenders and non-offenders with a SUD were classified with lower 
GM volume of the PFC when compared to those offenders and non-offenders without a 
SUD, signifying the relationship between long-term substance use and structural 
alterations of the PFC. This showed that relationship between reduced GM volume and 
elevated aggressive and/or violent behavior was independent of offender-status. The 
important aspect of this study, then, is the fact that it attempts to disentangle the 
confounded relationship between the two distinct categorical factors of focus and further 
develop treatment strategies accordingly. 
Upadhyay et al. (2010) investigated a different addictive substance – prescription 
opioids – in an effort to identify similar underlying neurobiological changes as those 
mentioned above. Investigators focused on recruiting both healthy control subjects and 
mild to moderate opioid-dependent individuals who did not present with any concurrent 
mental illness and who were not taking opioids for a current experience of chronic pain. 
Unsurprisingly, individuals classified as opioid-dependent were found to have less neural 
connectivity between the PFC and the amygdala, as well as less neural connectivity 
between the amygdala and both the NAv and the ACC. The duration of dependence on 
prescription opioids did not affect the connectivity between the PFC and the amygdala, 
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but was negatively correlated with the strength of connectivity between the amygdala and 
the NAc.  
Upadhyay et al. (2010) also specifically measured the volume of the amygdala 
structure and the integrity of white matter tracts in each study subject, and realized that 
both factors were positively correlated with the strength of neural connectivity to other 
brain structures – so smaller amygdala volume and poor integrity white matter tracts were 
associated with less strong neural connections between the amygdala and other brain 
structures. These structural abnormalities were significantly more extensive in those 
individuals dependent on opioid prescriptions. The investigators are careful to point out 
that opioids are known to significantly alter dendritic spine density, which may be the 
root cause of the brain alterations.  
 Gerrra et al. (2004) explored the relationship between the MAOA gene and SUDs 
as well as the relationship between the MAOA gene and vulnerability to aggressive 
and/or violent behavior. The investigators recruited 199 white male participants, 101 of 
whom were dependent on heroin and 95 of whom were healthy control subjects. Of those 
participants dependent on heroin, 52 exhibited aggressive and/or violent behavior and a 
diagnosis of a personality disorder. The investigators employed PCR and electrophoresis 
to determine genotype as either MAOA-3 (low-activity), MAOA-3.5, MAOA-4, or 
MAOA-5 (high-activity) based on the length of a particular region of the gene. The 
investigators employed the Buss-Durkee Hostility Inventory (BDHI) to rate episodes of 
aggression with a normal value of aggressiveness scoring below 60. Gerrra et al. (2004) 
found that the frequency of the low-activity MAOA-3 allele was significantly higher in 
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individuals with aggressive and/or violent tendencies than individuals with no history of 
aggressive and/or violent tendencies when comparing those with heroin use disorders. 
This indicated that the low-activity MAOA-3 allele contributes to individual 
susceptibility to aggressive and/or violent behavior.  
Schizophrenia and Personality Disorders  
The DSM-5 defines schizophrenia as the presentation of at least two of the 
following symptoms that occur for a significant amount of time over the span of a month: 
1) delusions, 2) hallucinations, 3) disorganized speech, 4) disorganized behavior, and 5) 
diminished emotional expression. Schizophrenia is further described as lower-than-
typical level of functioning in major life activities and must not be related to substance 
use. The DSM-5 describes antisocial personality disorder (APD) is characterized by a 
pervasive pattern of disregard for and violation of the rights of others and presents as at 
least three of the following symptoms that occur for a significant amount of time over the 
span of six months and: 1) failure to conform to social norms and lawful behavior, 2) 
deceitfulness and repeated lying, 3) impulsivity or failure to plan ahead, 4) irritability and 
aggressiveness, 5) reckless disregard for safety, 6) consistent irresponsibility, and 7) lack 
of remorse. Symptoms of APD first appear in those under 18 years old and constitute a 
diagnosis of conduct disorder (CD) before persisting into adulthood has APD.  
In order to develop a deeper understanding of the nature of dysfunctions in the 
neural circuit involved in emotional regulation, studies tend to focus on individuals with 
schizophrenia and antisocial personality disorder (APD), the two mental illnesses most 
commonly associated with impulsive aggression and violent behavior (Barkataki, 
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Kumari, Das, Taylor, & Sharma, 2006). Functional impairments in the brain have been 
used as evidence of neural pathology. For example, both schizophrenia and APD are 
often characterized by a reduction in whole brain size, predominantly diminished 
temporal and frontal lobe volume, as well as decreased amygdala-hippocampal complex 
volume. These volume reductions are linked to increased impulsivity and violence and 
decreased emotional processing (Barkataki et al., 2006).  
In one study in particular, 56 men were analyzed: 13 with APD, 13 with 
schizophrenia and a history of violence, 15 with schizophrenia and no history of violence, 
and 15 healthy and non-violent control subjects (Barkataki et al., 2006). The results of the 
study showed reduced whole brain volume in both the APD subjects and the violent 
schizophrenic subjects when compared with the healthy controls, as well as reduced 
hippocampal volume in the violent schizophrenic subjects when compared with the 
healthy controls. The comparisons between the two schizophrenic subject groups were 
particularly provocative. Of the subjects with schizophrenia, the violent group showed 
more significant reduction in whole brain and hippocampal volumes when compared with 
the non-violent group. Overall, the violent group exhibited a greater range of and more 
exaggerated brain abnormalities. These outcomes lead to the conclusion that the changes 
in volume of the brain structures are not due only to the acquisition of a mental disorder, 
but are more specifically related to violence.  
Blair (2001) also delved into the relationship between neurocognitive models of 
aggression and APD through the lens of the Violence Inhibition Mechanism (VIM) 
Model. According to Blair (2001), individuals with APD tend to exhibit a particular type 
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of aggression explained by the ‘inhibitory-control’ model, suggesting that violence is 
normally inhibited by the PFC, and therefore violent behavior in patients with PFC 
pathology alterations is a result of the patients’ inability to inhibit their violent impulses. 
In this way, individuals with APD reflect a lack of ability to appropriately self-integrate 
into society as a result of a dysfunctional system between the inhibitory PFC and the 
uncontrolled amygdala-hippocampal complex. This causes individuals with APD to react 
immediately to stimuli that are perceived as aggressive and/or threatening without the 
typical mechanisms in place to control this reactive behavior.  
These findings were supported by a number of different studies. For example, 
Gregory et al. (2012), noting that the population of individuals who display antisocial and 
violent behavior is significantly heterogeneous, aimed to identify structural abnormalities 
to detect differences between population members. The goal of this research was to 
actually distinguish between psychopathic (+P) and non-psychopathic (–P) individuals 
with APD. The investigators found an important difference between the two groups, 
namely that APD–P individuals exhibited GM brain volumes more similar to healthy 
control subjects than to APD+P individuals. This indicates that all cases of APD might 
not be correlated with reduced GM brain volume, but rather that psychopathy as a 
symptom of APD is correlated with reduced GM brain volume, specifically in the regions 
of the PFC (Gregory et al., 2012; Motzkin, Newman, Kiehl, & Koenigs, 2011). The 
investigators, pointing out that the PFC is involved in empathetic processing and moral 
reasoning, argued that these alterations may contribute to the antisocial behavior 
observed in psychopathy (Gregory et al., 2012). 
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Lachman, Nolan, Mohr, Saito, and Volavka (1998) investigated the 
polymorphism in the COMT gene resulting in the VAL (high-activity) to MET (low-
activity) substitution that is associated with a decrease in COMT expression and a 
subsequent increase in aggressive and/or violent behavior among individuals diagnosed 
with schizophrenia. The investigators scrutinized 55 individuals diagnosed with either 
schizophrenia or schizoaffective disorder with at least one prior inpatient psychiatric 
hospitalization. Of these subjects, 28 were classified as non-violent and 27 were 
classified as violent, with violent subjects being those with a documented history of 
multiple assaults on other persons. The results of the study indicated a significant 
relationship between the COMT polymorphisms and violent behavior, in which 64% of 
patients homozygous for the low-activity COMT allele were violent (indicating an 
activating effect) and 80% of patients homozygous for the high-activity COMT allele 
were non-violent (indicating a protective effect).  
These findings were supported in a later study by Jones et al. (2001), who 
compared 180 individuals who were diagnosed with schizophrenia to 173 healthy control 
subjects who were representative of the general population. Both the determination of 
genotype and the rating of aggression were completed by blinded investigators so that 
those determining genotype were unaware of participant behavior and those rating 
aggression were unaware of participant genotype. The investigators employed 
polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) 
assay to determine genotype as either high-activity homozygous, heterozygous, or low-
activity homozygous for the COMT allele. The investigators employed the Overt 
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Aggression Scale (OAS) to rate episodes of aggression into four categories of escalating 
violent behavior. OAS-1 (a score of 1 to 4) represents verbal aggression, OAS-2 (a score 
of 5 to 8) represents physical aggression against objects, OAS-3 (a score of 9 to 11) 
represents physical aggression against self, and OAS-4 (a score of 12 to 16) represents 
physical aggression against others. Two raters evaluated each participant, for a maximum 
possible OAS score of 32.  
Jones et al. (2001) found no significant difference in the distribution of genotypes 
between males and females, but did find a significant difference in the total OAS scores 
between males and females with males scoring significantly higher. There was a 
statistically significant effect of genotype on total OAS score, as the mean total OAS 
score for the high-activity homozygote was 23.5 and the mean total OAS score for the 
low-activity homozygote was 19.7. The investigators also made an interesting and 
unexpected discovery, that the mean total OAS score of the heterozygote was the lowest 
at 12.3, suggesting that heterozygosity may infer a protective effect against aggressive 
and/or violent behavior in individuals diagnosed with schizophrenia. The investigators 
ended their study with a discussion of the clinical implications of their findings, namely 
that COMT genotype may be regarded as a biological marker of aggression and that the 
biochemical pathway of COMT may be scrutinized for the development of 
pharmacological interventions to prevent or treat aggression.  
The DSM-5 defines borderline personality disorder (BPD) as characterized by a 
pervasive pattern of instability of interpersonal relationships, self-image, and affects 
beginning by early adulthood. These individuals present with at least five of the 
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following: 1) frantic efforts to avoid abandonment, 2) alternating between extremes of 
idealization and devaluation, 3) identity disturbance, 4) potentially damaging impulsivity, 
5) recurrent suicidal behaviors or self-mutilation, 6) marked reactivity of mood, 7) 
chronic feelings of emptiness, 8) inappropriate and intense anger, and 9) stress-related 
paranoid ideation. Tebartz et al. (2003) conducted research to tie BPD to alterations in 
volume of the PFC and limbic system. MRIs were used to compare the brain volumes of 
8 healthy control subjects and 8 individuals diagnosed with BPD, and found that those 
diagnosed with BPD exhibited volumes of the PFC, ACC, and amygdala-hippocampal 
complex, that were significantly smaller when compared to health controls. The 
investigators hypothesized that these changes were a result of both acquired and 
developmental brain dysfunction in relation to early traumatic experience.  
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CONCLUSION 
  
There has been much debate as to the positive and negative consequences of 
“medicalizing” mental illness, a process in which human conditions are alternatively 
defined as medical conditions with medical treatments. Proponents of incorporating 
neurobiological and genetic findings into the DSM-5 argue that it is a more humanistic 
approach, assigning a demonstrable biological and/or physiological defect to often 
misunderstood and stigmatized illnesses. Opponents of this suggestion argue that there is 
a lack of evidence for causation and that studies remain inconclusive as to the exact 
structural and functional alterations in the brain and their relation to mental disturbances.  
Martin, Pescosolido, and Tuch (2000) explore this question by determining five 
factors that affect the way in which the general public view and interact with individuals 
who have mental illnesses. These factors include: 1) the nature of the individual’s 
behavior, 2) the cause of the individual’s behavior, 3) the perceived dangerousness of the 
individual’s behavior, 4) the label of ‘mental illness’, and 5) the socio-demographic 
categorizations of the individual. The authors found that members of the general public 
who attribute the symptoms of mental illness to root biological and/or physiological 
causes are more willing to interact with mentally ill individuals than those members of 
the general public who attribute the symptoms of mental illness to poor character or 
misaligned morals. The authors found that even the term ‘mental illness’ served to create 
a distance between the general public and individuals living with the illness, supporting 
the recommendations of Corrigan and Watson (2004) to promote a transformation in the 
language used to refer to individuals diagnosed with mental illness.  
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Eichelman (1988), in a review of both animal and human studies, postulated that 
pharmacological findings concerning the dopaminergic, serotonergic, catecholaminergic, 
and GABAergic influences of neurotransmitters are essential for the effective treatment 
of aggressive/violent symptoms of certain mental illness. The author suggested that 
supplementing pharmacological approaches with behavioral and social learning 
approaches to reducing aggressive and/or violent behaviors will improve treatment 
adherence. Within the cases he examined, Eichelman (1988) defined aggressive behavior 
as that which “leads to … the destruction of a target entity” (p. 31) and defines violent 
behavior as “destructive aggression that inflicts personal damage on persons or property” 
(p. 31). Because this behavior is multifaceted, treatment also requires a multifaceted 
approach.  
Eichelman (1988) described the pharmacological interventions for aggressive 
and/or violent behavior to include the regulation of neurotransmitter systems. For 
example, the author reported that dietary supplementation of the amino acid precursor 
(tryptophan) or enhanced activity of the synthesizing enzyme (tryptophan hydroxylase) of 
serotonin has been correlated with reduced aggression in animal studies. As a result, 
precursors of serotonin have been tested for anti-aggressive effects in human studies. 
Secondly, the author found that administration of lithium or beta-blockers decreases the 
functional availability of norepinephrine in the brain and has been correlated with 
reduced aggression in animal studies. These findings have been reflected in human 
studies, as the use of lithium was shown to decrease the number of aggressive infractions 
incurred by a prisoners typically exhibiting violent behaviors, children diagnosed with 
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conduct-disorders and personality-disorders, and adults diagnosed with schizophrenia and 
organic brain disorders. In addition, the author discovered that injection of GABA into 
olfactory bulbs and the use of benzodiazepines to enhance the activity of the GABAergic 
system have been correlated with reduced aggression in animal studies. These findings 
have also been reflected in human studies, as benzodiazepines have been found to reduce 
aggression in anxious and hostile patients as well as aggressive and psychotic patients.  
Eichelman (1988) was quick to point out that pharmacological interventions, 
although effective, are insufficient for the treatment of aggressive and/or violent behavior 
associated with certain mental illnesses. In fact, he emphasized the inevitability of failed 
treatment unless the control of neurotransmitter systems is accompanied by the 
behavioral and social control of symptoms. The author recommends that systematic 
treatment with medication is followed by good clinical care and attention. 
Therefore, it is important to recognize that aggressive and/or violent behavior is 
not solely attributable to alterations in brain structure and function. This behavior is also 
influenced by both genetics and the environment. Craig (2007) points to a recognized 
‘cycle of violence’ in which children of aggressive and/or violent parents will grow up to 
be aggressive and/or violent parents. The difficulty with understanding this trend is in 
deciphering whether it is due to genetic factors passed along from parents to their 
children or whether it is due to behavioral factors that are modeled by parents for their 
children.  
Lastly, it is essential to keep in mind that very rarely will mental illness present in 
isolation. Brady and Sinha (2005) explored the well-established high rate of co-
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occurrence between SUDs and other psychiatric disorders, which are intimately 
connected in both etiology and symptomology. The authors first examined the 
relationship between MDD and SUDs, finding rate of comorbidity ranging from 32% to 
54%, so individuals with MDD had a heightened risk of developing a SUD and 
individuals with a SUD had a heightened risk of developing MDD when compared to the 
general population. A similar relationship was found between SUDs and schizophrenia, 
in that substance-use has been shown to contribute to poor social function and 
exacerbation of symptoms in those diagnosed with schizophrenia. These are important 
points to keep in mind in the diagnosis and treatment of mental illness, and evaluation of 
biological and physiological mechanisms behind the aggressive and/or violent symptoms 
associated with these diagnoses.  
Aggression and violence are often misunderstood and misattributed as a result of 
moral failing or poor self-control. With a deeper and boarder understanding of brain 
structures and neurological pathways, it is possible to more accurately and effectively 
evaluate this type of behavior. It is the hope of researchers in the field of medicine and 
psychology that the medicalization of mental illness will reduce stigma and 
discrimination and lead to improved pharmacological and behavioral interventions to 
reduce aggressive and/or violent symptoms. 
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